|
|
CPG 7909 |
|
Vaxjo ID |
284 |
|
Vaccine Adjuvant Name |
CPG 7909 |
|
Adjuvant VO ID |
VO_0005772
|
|
Description |
CPG 7909 (lefitolimod/MGN1703) is a dumbbell-shaped DNA molecule that activates Toll-like receptor 9 (TLR9) in plasmacytoid dendritic cells and B cells, inducing immune responses. |
|
Stage of Development |
Clinical Trial |
|
Host Species for Testing |
Human |
|
Components |
A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide® ISA-51 in Patients With Cancer. |
|
Structure |
Dumbbell-shaped DNA molecule triggering TLR9 signaling |
|
Preparation |
Administered subcutaneously (s.c.) at 120 mg weekly for 8 weeks |
|
Dosage |
120 mg s.c. once per week, in combination or alone during trial. |
|
Function |
Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial |
|
Safety |
Generally safe. Most adverse events were mild (injection site reactions, fatigue). One severe event resolved without complications |
| References |
Gunst et al., 2023: Gunst JD, Højen JF, Pahus MH, Rosás-Umbert M, Stiksrud B, McMahon JH, Denton PW, Nielsen H, Johansen IS, Benfield T, Leth S, Gerstoft J, Østergaard L, Schleimann MH, Olesen R, Støvring H, Vibholm L, Weis N, Dyrhol-Riise AM, Pedersen KBH, Lau JSY, Copertino DC Jr, Linden N, Huynh TT, Ramos V, Jones RB, Lewin SR, Tolstrup M, Rasmussen TA, Nussenzweig MC, Caskey M, Reikvam DH, Søgaard OS. Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial. Nature medicine. 2023; 29(10); 2547-2558. [PubMed: 37696935].
|
|
